Hangzhou Diagens Biotechnology (HKG:2526) raised HK$719.8 million in net proceeds from its initial public offering in Hong Kong.

The final offer price was set at HK$99.00 per H-share, according to a Friday after-market filing with the Hong Kong Stock Exchange.

The Chinese biotechnology company offered 8.0 million H-shares in the global offering.

The Hong Kong public offer was 1,073.37 times subscribed, with a final allocation of 799,950 shares, representing 10% of the total offering.

The international offering was 3.45 times subscribed, with a final allocation of 7.2 million shares, or 90% of the total offering.

Diagens Biotechnology is scheduled to debut on the Hong Kong bourse on Monday, March 30.